Enanta Pharma (ENTA) Misses Q2 EPS by 14c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.53), $0.14 worse than the analyst estimate of ($1.39). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $20.65 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal